Modulation of immune cell trafficking across the blood-brain barrier has not only introduced
a therapeutic avenue for multiple sclerosis (MS) but also represents an example of reverse …

Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as
represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY). However, the …

Objective Novel treatments such as natalizumab and fingolimod achieve their therapeutic
efficacy in multiple sclerosis (MS) by blocking access of subsets of immune cells into the …

Applying microarray technology to identify new diagnostic and prognostic markers in
peripheral blood cells (PBC) after therapeutic intervention opens great perspectives …

Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central
nervous system afflicting nearly three million individuals worldwide. Neuroimmune …

Objective: We undertook a systems immunology approach of the adaptive immune system in
multiple sclerosis (MS), overcoming tradeoffs between scale and level of detail, in order to …

Multiple sclerosis (MS) is an inflammatory neurodegenerative disorder with putative
autoimmune origin. The disease starts earlier than current diagnostic criteria can detect and …

In the CNS, no pathway dedicated to immune surveillance has been characterized for
preventing the anti-CNS immune responses that develop in autoimmune neuroinflammatory …

Multiple sclerosis (MS) is a chronic disease that is characterized by the inappropriate
invasion of lymphocytes and monocytes into the central nervous system (CNS), where they …

Multiple Sclerosis (MS) is considered the most frequent inflammatory demyelinating disease
of the central nervous system (CNS). It occurs with a variable prevalence across the world. A …